All In Biotech

Drug Trial Radar · NCT03901105

Evaluation of Flortaucipir PET Signal and Cognitive Change in Early Alzheimer's Disease

Evaluation of the Relationship Between Baseline Flortaucipir PET Signal and Cognitive Change in Subjects With Early Alzheimer's Disease Participating in the I8D-MC-AZES Protocol Addendum D5010C00009 (2.1) (Tau Imaging)

Last checked: Nov 20, 2026Latest source record: Aug 28, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

205

Actual

Start

Mar 28, 2019

Primary completion

Apr 28, 2019

Study completion Apr 28, 2019

Sponsor

Lead sponsor
Avid RadiopharmaceuticalsIndustry
Sponsor type
Industry
First posted
Apr 3, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 55 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate whether visual interpretation of flortaucipir-PET (positron emission tomography) scans, examining patterns of tracer uptake at baseline, can predict the rate of clinically-meaningful cognitive decline due to AD after 18 months. All scans are acquired from cohorts of a previously completed study, I8D-MC-AZES (NCT02245737, lanabecestat, Eli Lilly and Company sponsor).

Conditions

  • Alzheimer Disease

Interventions

  • flortaucipir F18Drug

    No study drug will be administered. Scans previously acquired from Study I8D-MC-AZES (NCT02245737, Eli Lilly and Company sponsor) at baseline will be read by independent, blinded readers. IV injection, 240 megabecquerel (MBq) (6.5 mCi), single dose in AZES

  • Brain PET ScanProcedure

    positron emission tomography (PET) scan of the brain

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Risk Ratio for AD Symptom Progression on CDR-SBTime frame: Within 18 months of scan

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • American College of Radiology

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.